Equitec Proprietary Markets’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Equitec Proprietary Markets’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$1.1M	Buy	+8,370	New	+$740K	0.29%	34

Other funds holding EIDX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Equitec Proprietary Markets's EIDX Position: Q4 2020 in Review

Equitec Proprietary Markets opened a new position in Eidos Therapeutics, Inc. Common Stock (EIDX) in Q4 2020: 8,370 shares worth $1.1M. The stake represents 0.29% of the portfolio and ranks #34 among its holdings.

121 funds tracked by Wall St. Rank hold EIDX as of Q4 2020.

Equitec Proprietary Markets held 8,370 shares of Eidos Therapeutics, Inc. Common Stock worth $1.1M as of Q4 2020.
Eidos Therapeutics, Inc. Common Stock was a new Equitec Proprietary Markets position in Q4 2020.
Eidos Therapeutics, Inc. Common Stock made up 0.29% of Equitec Proprietary Markets's portfolio in Q4 2020, its #34 holding.
121 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q4 2020.

Based on Equitec Proprietary Markets's 13F filing for Q4 2020, filed 26 Jan 2021.